A new protocol for seminoma is now available. It replaces SWENOTECA VII from October 1, 2014.
The major changes in the guideline are:
Patients with tumour size 4 cm or less and without invasion of the rete testis are recommended surveillance.
Patients with tumour size more than 4 cm or invasion of the rete testis are recommended adjuvant carboplatin. Surveillance may be an option to those patients not wanting adjuvant treatment.
Stage II A
Stage II B-IV
Radiotherapy for cancer in situ (CIS) in the contralateral testicle:
Many SWENOTECA centers have prescribed an average target dose of 16 Gy, 2 Gy x 8. And therefore a part of the testicle has got a dose < 16 Gy. There have been relapses after irradiation for CIS. Our new recommendation is therefore: The target dose should be average 18 Gy, 2 Gy x 9, in order to get a minimum dose of 17 Gy in the testicle.
For full information see SWENOTECA IX